Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Fei-Fei Li
AddedFeb 13, 2024
UpdatedJun 28, 2026
Fei-Fei Li

Fei-Fei Li

Cofounder & CEO, World Labs

CrunchbaseLinkedInThe Org

Fei-Fei Li's Career

World Labs
World Labs

San Francisco, CA, US

Cofounder & CEO
Twitter
Twitter

San Francisco, CA, US

Board Member· Board
Eikon Therapeutics
Eikon Therapeutics

Hayward, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Fei-Fei Li's Career

World Labs
World Labs
Series B$1.2B2024San Francisco, CA, US
Cofounder & CEO

Recent news

AI pioneer Fei-Fei Li's World Labs raises $1 billion in fundingReuters · 2026
AI Pioneer Fei-Fei Li's Startup World Labs Raises $1 BillionBloomberg · 2026
Fei-Fei Li’s World Labs speeds up the world model race with Marble, its first commercial productTechCrunch · 2025

Leadership at World Labs

Ben MildenhallBen MildenhallCofounder
Christoph LassnerChristoph LassnerCofounder
Justin JohnsonJustin JohnsonCofounder

Similar to World Labs

RunwayRunwayNew York City, NY, USAI Softwareest. 2018RunwayNew York City, NY, US · est. 2018

Runway develops generative AI and world models for video, image, and interactive media creation.

Series E · $551.5M86
General IntuitionGeneral IntuitionNew York, NY, USest. 2025General IntuitionNew York, NY, US · est. 2025

General Intuition builds embodied AI agents and world models that learn spatial-temporal reasoning from interactive gameplay data.

Series A · $453.7M31
Google DeepMindGoogle DeepMindLondon, GBest. 2010Google DeepMindLondon, GB · est. 2010

Google DeepMind is an AI research and development company based in London.

Acquired Subsidiary · $500M3k
NVIDIANVIDIASanta Clara, CA, USGpus, Softwareest. 1993NVIDIASanta Clara, CA, US · est. 1993

Global tech firm specializing in 3D graphics processors and software.

Public · $24.1B42k
Twitter
Twitter
Acquired$12.9B7.5k2006San Francisco, CA, US
Board Member· Board

Recent news

Parallel Web Systems hits $2B valuation five months after its last big raiseTechCrunch · 2026
Particle’s AI news app listens to podcasts for interesting clips so you you don’t have toTechCrunch · 2026
Will Musk vs. Trump affect xAI’s $5 billion debt deal?Startups | TechCrunch · 2025

Leadership at Twitter

Elad GilElad GilVP of Corporate Strategy
Linda YaccarinoLinda YaccarinoCEO
Elon MuskElon MuskBoard Member
Bret TaylorBret TaylorBoard Member
Jack DorseyJack DorseyCo-Founder
Omid KordestaniOmid KordestaniBoard Member
Eikon Therapeutics
Eikon Therapeutics
Series C$772M3742019Hayward, CA, US
Board Member· Board

Leadership at Eikon Therapeutics

Robert TjianRobert TjianBoard Member
Dror BermanDror BermanBoard Member
Roger PerlmutterRoger PerlmutterBoard Member
Larry LaskyLarry LaskyBoard Member
Xavier DarzacqXavier DarzacqCo-Founder
Luke LaviLuke LaviCo-Founder

Similar to Eikon Therapeutics

Eikonizo TherapeuticsEikonizo TherapeuticsCambridge, MA, USTherapeuticsest. 2017Eikonizo TherapeuticsCambridge, MA, US · est. 2017

Eikonizo: Innovating brain-penetrant therapies for neurodegenerative diseases.

Seed · $2M13
Eikonoklastes TherapeuticsEikonoklastes TherapeuticsCincinnati, OH, USImmunotherapiesest. 2019Eikonoklastes TherapeuticsCincinnati, OH, US · est. 2019

Eikonoklastes pioneers next-gen TF immunotherapies, targeting key tumor microenvironment components.

Series A · $6M7
Entrada TherapeuticsEntrada TherapeuticsBoston, MA, USBiologics, Therapeuticsest. 2016Entrada TherapeuticsBoston, MA, US · est. 2016

Entrada Therapeutics: A global biotech firm developing intracellular biologics for devastating diseases.

Public · $201.6M130
Triplet TherapeuticsTriplet TherapeuticsCambridge, MA, USBiotechnologyest. 2019Triplet TherapeuticsCambridge, MA, US · est. 2019

Triplet Therapeutics: Pioneering biotech firm developing transformative treatments for genetic diseases.

Series A · $59M36

Fei-Fei Li's Co-Investors

Jure LeskovecJure LeskovecCo-invested · Coactive AI Series A · 2 dealsEli CollinsEli CollinsCo-invested · Coactive AI Series A · 2 dealsAlexandr WangAlexandr WangCo-invested · Twelve Labs SeedOren EtzioniOren EtzioniCo-invested · Twelve Labs SeedJack ConteJack ConteCo-invested · Twelve Labs SeedAaron KatzAaron KatzCo-invested · Twelve Labs SeedSilvio SavareseSilvio SavareseCo-invested · Twelve Labs SeedDug SongDug SongCo-invested · Twelve Labs Seed

Fei-Fei Li's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Fei-Fei Li

Rosalind PicardRosalind PicardBoard Member · EmpaticaJeff DeanJeff DeanBoard Member · GRAILMaja J MataricMaja J MataricCo-Founder · EmbodiedAdam CheyerAdam CheyerBoard Member · Allen Institute for Artificial IntelligenceSamuel MaddenSamuel MaddenCo-Founder · Volt Active DataHao LiHao LiCo-Founder · iCarbonX